The company has received a total of 360 million yen in investments from Osaka University Venture Capital Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., and Chishima Real Estate Co., Ltd.
With this latest round of funding, the company has raised a total of 1.48 billion yen.

Preparations for clinical trials have been progressing smoothly so far (completion of investigational drug manufacturing, completion of coordination with clinical trial institutions, etc.), and with this funding, the company plans to begin clinical trials for metastatic and recurrent HER2-negative breast cancer, including triple-negative breast cancer.